We are live on
!
Find out more
Axa Portfolio holdings
AUM
$91.9M
1-Year Est. Return
27.41%
This Fund
S&P 500
This Quarter
Est. Return
+2.56%
1 Year Est. Return
+27.41%
3 Year Est. Return
+100.68%
5 Year Est. Return
+129.89%
10 Year Est. Return
+554.73%
AUM
$23B
AUM Growth
+$654M
(+2.9%)
Cap. Flow
+$6.71M
Cap. Flow
% of AUM
0.03%
Top 10 Holdings %
Top 10 Hldgs %
15.45%
Holding
1,532
New
151
Increased
540
Reduced
484
Closed
141
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Verizon
VZ
|
+$284M |
| 2 |
Deutsche Bank
DB
|
+$159M |
| 3 |
Norfolk Southern
NSC
|
+$108M |
| 4 |
HP
HPQ
|
+$92.2M |
| 5 |
DD
Du Pont De Nemours E I
DD
|
+$80.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$161M |
| 2 |
Ford
F
|
+$87.9M |
| 3 |
Whirlpool
WHR
|
+$74M |
| 4 |
PNC Financial Services
PNC
|
+$72.9M |
| 5 |
Eastman Chemical
EMN
|
+$72.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 15.62% |
| 2 | Technology | 14.22% |
| 3 | Financials | 13.17% |
| 4 | Industrials | 11.49% |
| 5 | Energy | 8.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
VTLE
676
DELISTED
Vital Energy
VTLE
| $2.59M | 0.01% |
5,000
+350
| +8% | +$179K |
|
|
DBV
677
DELISTED
Invesco DB G10 Currency Harvest Fund
DBV
| $2.58M | 0.01% |
98,810
+11,980
| +14% | +$305K |
|
678
Bio-Techne
TECH
$11.3B
| $2.58M | 0.01% |
121,004
+6,300
| +5% | +$142K |
|
|
AKAO
679
DELISTED
Achaogen Inc
AKAO
| $2.58M | 0.01% |
+167,046
| New | +$2.89M |
|
680
Vanguard S&P 500 ETF
VOO
$1.04T
| $2.57M | 0.01% |
15,000
| – | – |
|
|
DGL
681
DELISTED
Invesco DB Gold Fund
DGL
| $2.54M | 0.01% |
59,010
+14,740
| +33% | +$640K |
|
682
WaFd
WAFD
$2.44B
| $2.53M | 0.01% |
108,500
+86,400
| +391% | +$1.96M |
|
683
Extra Space Storage
EXR
$29B
| $2.53M | 0.01% |
52,100
+5,589
| +12% | +$259K |
|
684
Dover
DOV
$25.5B
| $2.52M | 0.01% |
38,130
-1,156,063
| -97% | -$71.9M |
|
685
iShares MSCI United Kingdom ETF
EWU
$3.71B
| $2.52M | 0.01% |
61,150
-5,050
| -8% | -$208K |
|
|
APOL
686
DELISTED
Apollo Education Group Inc Class A
APOL
| $2.52M | 0.01% |
73,500
-12,500
| -15% | -$406K |
|
|
BCR
687
DELISTED
CR Bard Inc.
BCR
| $2.51M | 0.01% |
16,938
-1,890
| -10% | -$262K |
|
688
JetBlue
JBLU
$1.61B
| $2.5M | 0.01% |
288,300
+225,400
| +358% | +$1.98M |
|
689
Chord Energy
CHRD
$8.59B
| $2.5M | 0.01% |
60,000
-15,000
| -20% | -$635K |
|
690
SM Energy
SM
$9.82B
| $2.5M | 0.01% |
35,000
-15,000
| -30% | -$1.17M |
|
691
Dr. Reddy's Laboratories
RDY
$9.62B
| $2.49M | 0.01% |
283,500
| – | – |
|
692
Kelly Services Class A
KELYA
$571M
| $2.48M | 0.01% |
104,400
-108,638
| -51% | -$2.65M |
|
|
ENH
693
DELISTED
Endurance Specialty Holdings Ltd
ENH
| $2.48M | 0.01% |
46,000
-4,600
| -9% | -$245K |
|
|
ORB
694
DELISTED
ORBITAL SCIENCES CORP
ORB
| $2.46M | 0.01% |
88,300
-4,318
| -5% | -$114K |
|
695
iShares MSCI Australia ETF
EWA
$1.28B
| $2.46M | 0.01% |
95,215
| – | – |
|
696
Agios Pharmaceuticals
AGIO
$1.96B
| $2.46M | 0.01% |
62,741
+3,268
| +5% | +$109K |
|
|
CB
697
DELISTED
CHUBB CORPORATION
CB
| $2.45M | 0.01% |
27,410
+2,400
| +10% | +$210K |
|
698
Netflix
NFLX
$324B
| $2.43M | 0.01% |
+483,000
| New | +$2.77M |
|
|
NBL
699
DELISTED
Noble Energy, Inc.
NBL
| $2.4M | 0.01% |
33,750
-40,476
| -55% | -$2.68M |
|
700
RLJ Lodging Trust
RLJ
$1.67B
| $2.39M | 0.01% |
89,392
+9,792
| +12% | +$250K |
|
Similar funds
VI
FA
PBCM
CCAM
GBA
AWP
HI
DCA
Axa's Q1 2014 Portfolio in Review
As of Q1 2014, Axa held 1,532 positions worth $23B, up 2.9% from $22.3B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Axa's Q1 2014 filing shows 151 new, 540 increased, 484 reduced and 141 closed positions. Its largest new stake was Celanese: 949,936 shares worth $52.7M. The largest sale was Eli Lilly, an estimated $161M.
By sector, the portfolio is most concentrated in Healthcare at 16% of assets, down from 16% a quarter earlier, followed by Technology and Financials.
- Axa's largest Q1 2014 buy was Celanese: 949,936 shares worth $52.7M.
- Axa added most to Verizon in Q1 2014, an estimated $284M increase.
- Axa's biggest Q1 2014 reduction was Eli Lilly, cutting an estimated $161M.
- Axa fully exited Avon Products, Inc. in Q1 2014, selling an estimated $53.7M.
- Axa's ten largest holdings make up 15% of its $23B portfolio in Q1 2014.
- Axa opened 151 new positions and closed 141 in Q1 2014.
- Axa's portfolio value rose 2.9% quarter-over-quarter to $23B.
Based on Axa's 13F filing for Q1 2014, filed 13 May 2014.